StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note issued to investors on Friday. The firm issued a sell rating on the stock. NovaBay Pharmaceuticals Stock Down 5.4 % Shares of NYSE NBY opened at $0.13 on Friday. The company has a fifty day moving average price of […]
Item 2.01 Completion of Acquisition or Disposition of Assets On March 25, 2024, NovaBay Pharmaceuticals, Inc. completed the sale of its wholly-owned subsidiary, DERMAdoctor,.
Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova® physician dispensed and OTC channels, and from branded wound care.
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.